Phase II Single Arm Trial of Low Dose Capecitabine in Patients With Advanced Breast Cancer
Status:
Not yet recruiting
Trial end date:
2028-12-01
Target enrollment:
Participant gender:
Summary
This is a phase II study aiming at evaluating capecitabine prospectively at a dose of 1000 mg
once daily in patients with advanced breast cancer who are ≥60 years of age, or frail at any
age, with a greater risk of complications and poorer outcomes with other treatments.